Roughan Sheedy

Leader in AI powered Drug Development and Precision Medicine Superior Science and Risk-Sharing Business Models DYNAMIKA, Cloud AI-Powered Platform for Data Management Smart Imaging Strategy to Accelerate Drug Development
Roughan Sheedy 2

Roughan Sheedy

Chief Executive Officer of IAG
Experienced Life Science Executive.
Roughan Sheedy, previously COO at Invicro, brings over 20 years of success in leading and scaling high-performance imaging clinical research and technology companies. Roughan has held senior roles in Finance and Commercial and has a depth of experience of driving global growth and expansion throughout Europe, the US and Asia.

Jon Himoff

Leader in AI powered Drug Development and Precision Medicine Superior Science and Risk-Sharing Business Models DYNAMIKA, Cloud AI-Powered Platform for Data Management Smart Imaging Strategy to Accelerate Drug Development
Himoff

Jon Himoff

Chief Product Officer
Leading Product Design and Engineering organization with P&L ownership and customer focus.
Turning concepts into new tech-driven businesses and growing them rapidly, is what I enjoy working on the most. I went from blank sheets of paper to an idea, to team creation, to early stage funding, to a multi-million $ sale to a US public company. I have also worked with companies that have great assets, but have lacked a fresh, energetic approach which focuses on next generation offerings and reaches more prospective customers faster.

Michael Clark, PMP

Leader in AI powered Drug Development and Precision Medicine Superior Science and Risk-Sharing Business Models DYNAMIKA, Cloud AI-Powered Platform for Data Management Smart Imaging Strategy to Accelerate Drug Development
MichaelClark

Michael Clark, PMP

Chief Operating Officer
Building Teams and Scalling Capabilities to Deliver Global Scale Imaging Clinical Trials
A Senior Clinical Director with extensive experience in undertaking strategic planning, oversight and execution of clinical programs and leading staff across multiple project areas globally. Skilled in needs assessment, quality assurance, managing programmes, communicating deadlines and completing projects within budget and on-time. Committed to achieving and exceeding targets in a drive to meet business objectives with strong clinical expertise and stakeholder management abilities.

Christophe Berthoux, MD

Leader in AI powered Drug Development and Precision Medicine Superior Science and Risk-Sharing Business Models DYNAMIKA, Cloud AI-Powered Platform for Data Management Smart Imaging Strategy to Accelerate Drug Development
archimed-christophe-2_3

Christophe Berthoux, MD

Chairman
Biotech and Pharma Drug Development Strategy
Christophe is IAG's Chairman and an Operating Parter in ArchiMed, independent investment firm specialized in the Healthcare industries. Prior to this, he has spent his 20+ year career within the Clinical Research industry, and brings extensive expertise and knowdledge of this sector. Christophe was CEO of UK based Synexus, a leading global SMO and European CEO of Citoxlab Christophe Berthoux, is a doctor in veterinary medicine and holds an MBA from Purdue University, Indiana (US).

Dr. Jan Lundberg, MD, PhD

Leader in AI powered Drug Development and Precision Medicine Superior Science and Risk-Sharing Business Models DYNAMIKA, Cloud AI-Powered Platform for Data Management Smart Imaging Strategy to Accelerate Drug Development
Jan Lundberg_TB Alliance Board of Directors

Dr. Jan Lundberg, MD, PhD

Chair of Scientifc Advisory Board
Novel Drug Discovery and Development
Jan joined IAG in 2018 to chair IAG’s distinguished board of in-house scientists, imaging experts and academic collaborators and closely work with biotech and pharma partners. Jan's expertise and many years of experience are in the critical assessment of novel therapeutic agents and strategic positioning to maximize the chances of their success. Dr. Lundberg, a scientist with over 22 years of experience in global pharmaceutical R&D. Until recently he was heading R&D organization for Ely Lilly and previously – global research for AstraZeneca. He was involved with discovery of more than 200 candidate drugs and 22 approved products across multiple therapeutic areas, including immunology, oncology and neurology; he has been instrumental for the use of imaging cross therapeutic area projects including amyloid and tau PET imaging in Alzheimer’s dementia. His career began in Karolinska institutet, where he was a professor of pharmacology and a co-founder of Aerocrine AB.

Dr. Olga Kubassova, PhD

Leader in AI powered Drug Development and Precision Medicine Superior Science and Risk-Sharing Business Models DYNAMIKA, Cloud AI-Powered Platform for Data Management Smart Imaging Strategy to Accelerate Drug Development
IMG_20200624_105741

Dr. Olga Kubassova, PhD

IAG's President and Founder
Life Science Innovator, Venture Partner and Bio-Pharma Drug Development Strategist
Founder of IAG and life science innovator, mathematician with expertise in actively managing innovation in life science companies, asset positioning, and strategy. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is an active researcher, with over 80 publications, books and book chapters. She is a scientific adviser to the UK government and EU funding bodies. Her ambition is to bring truly disruptive technologies, artificial intelligence and best of machine learning to clinical practice and research, while expanding IAG's footprint and partnerships.